Trial reportTranslational psychiatry2026
Glutamate- and GABA-targeted drugs for Cc-occurring bipolar and alcohol use disorders: a randomized, double-blind, placebo-controlled, crossover study of N-acetylcysteine, gabapentin, and placebo.
Trial report in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03220776 (Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Forty percent of people with bipolar disorder (BD) develop alcohol use disorder (AUD), with co-occurring AUD substantially worsening the course of BD. Though efficacious treatments remain elusive, frontal glutamate and GABA dysregulation represent promising targets for intervention. This study evaluated the ability of two adjunctive medications, N-acetylcysteine (NAC) and gabapentin, to modulate glutamate and GABA (primary) and to reduce heavy drinking and depressive symptoms (exploratory) in people with BD + AUD. Fifty-four individuals meeting DSM-5 criteria for BD + AUD were enrolled in a randomized, double-blind, placebo-controlled, crossover study, with 3, 1-week conditions (NAC, gabapentin, placebo). Medication effects on dorsal anterior cingulate cortex (dACC) glutamate+glutamine (Glx) and GABA levels, via proton MR spectroscopy, and percent heavy drinking days (%HDD) and depressive symptoms were evaluated with linear mixed models. Forty-nine participants (M[SD] age=41.0[12.2], 51% female, 74% white) provided 121-131 posttreatment-MRI scans, depending on analysis. Medications were well-tolerated, and adherence was excellent. DACC Glx (F = 4.76, p = 0.012) but not GABA (F = 0.96, p = 0.388) levels significantly differed across conditions, with only NAC (M[SD] = 21.50[2.55]) demonstrating significantly different(lower) glutamate levels relative to placebo (M[SD] = 22.59[2.56]; p = 0.003; SMD = 0.43). %HDD (F = 3.90, p = 0.025) also significantly differed across conditions, again with only NAC (M[SD] = 31.86[4.60]) demonstrating significantly different(lower) %HDD relative to placebo (M[SD] = 40.94[4.55]; p = 0.015; SMD = 0.33), though neither NAC (p = 0.128) nor gabapentin (p = 0.228) differed from placebo on depressive symptoms. These results support the development of mechanistic clinical trials targeting glutamatergic dysfunction in people with BD + AUD. Trial Registration: https://clinicaltrials.gov/study/NCT03220776 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.